Advertisement

Topics

Oxford BioMedica could get $100m following CAR-T approval

08:21 EDT 1 Sep 2017 | pharmaphorum

UK biotech Oxford BioMedica could earn more than $100 million from Novartis for providing a key component in the recently approved CAR-T cancer cell therapy. The FDA this week approved Novartis’ chimeric antigen receptor T-cell (CAR-T) therapy ...

Original Article: Oxford BioMedica could get $100m following CAR-T approval

NEXT ARTICLE

More From BioPortfolio on "Oxford BioMedica could get $100m following CAR-T approval"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...